Literature DB >> 1435744

Determinants of antifolate cytotoxicity: folylpolyglutamate synthetase activity during cellular proliferation and development.

J Barredo1, R G Moran.   

Abstract

Previous studies have documented the metabolism of a broad range of folate antimetabolites to polyglutamate derivatives by the enzyme folylpoly-gamma-glutamate synthetase (FPGS). The activity of the more recently developed classes of antifolates directed against thymidylate synthase and de novo purine synthesis is sufficiently dependent on polyglutamation that these compounds should be specifically cytotoxic to any normal or malignant proliferating cell expressing this enzyme. We have studied the patterns of expression of FPGS in mammalian cells and tissues during rapid growth, growth arrest, differentiation, and embryonic development. During embryogenesis in the rat, FPGS levels in liver and brain were higher during the period of proliferative activity and then dropped to a level characteristic of the adult organs. However, the levels in liver were substantially higher than those in brain at any given time. This pattern was mimicked in mouse C3H 10T1/2 embryo fibroblast cells, in which FPGS activity decreased after cessation of growth but then remained at a lower steady state level during an extended period of postconfluent culture. Enzyme activity also dropped after the differentiation of human HL-60 promyelocytic leukemia cells. In a human homolog of these experimental systems, FPGS levels were below the limits of detection in circulating mature human hematopoietic cells of the granulocytic, lymphoblastic, and erythrocytic lineages. In striking contrast, substantial levels of FPGS were found in circulating lymphoblasts from eight patients with acute lymphoblastic leukemia. The levels of FPGS found in these transformed stem cells would help to explain the sensitivity of many acute lymphoblastic leukemias to folate antimetabolites. We concluded that expression of FPGS is regulated by at least two mechanisms, one of which is linked to proliferation and the other of which controls enzyme levels after differentiation and is tissue specific.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1435744

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  8 in total

1.  Folylpolyglutamate synthetase gene transcription is regulated by a multiprotein complex that binds the TEL-AML1 fusion in acute lymphoblastic leukemia.

Authors:  Guy J Leclerc; Christopher Sanderson; Stephen Hunger; Meenakshi Devidas; Julio C Barredo
Journal:  Leuk Res       Date:  2010-06-09       Impact factor: 3.156

2.  A mouse gene that coordinates epigenetic controls and transcriptional interference to achieve tissue-specific expression.

Authors:  Alexandra C Racanelli; Fiona B Turner; Lin-Ying Xie; Shirley M Taylor; Richard G Moran
Journal:  Mol Cell Biol       Date:  2007-11-12       Impact factor: 4.272

3.  Synthesis and evaluation of a classical 2,4-diamino-5-substituted-furo[2,3-d]pyrimidine and a 2-amino-4-oxo-6-substituted-pyrrolo[2,3-d]pyrimidine as antifolates.

Authors:  Aleem Gangjee; Jie Yang; John J McGuire; Roy L Kisliuk
Journal:  Bioorg Med Chem       Date:  2006-09-20       Impact factor: 3.641

4.  Murine cytomegalovirus stimulates cellular thymidylate synthase gene expression in quiescent cells and requires the enzyme for replication.

Authors:  G Gribaudo; L Riera; D Lembo; M De Andrea; M Gariglio; T L Rudge; L F Johnson; S Landolfo
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

Review 5.  Folate metabolism: a re-emerging therapeutic target in haematological cancers.

Authors:  Martha M Zarou; Alexei Vazquez; G Vignir Helgason
Journal:  Leukemia       Date:  2021-03-11       Impact factor: 11.528

6.  Analysis of folylpoly-gamma-glutamate synthetase gene expression in human B-precursor ALL and T-lineage ALL cells.

Authors:  Guy J Leclerc; Gilles M Leclerc; Ting Ting Hsieh Kinser; Julio C Barredo
Journal:  BMC Cancer       Date:  2006-05-17       Impact factor: 4.430

7.  Subcutaneous administration, higher age and lower renal function are associated with erythrocyte methotrexate accumulation in Crohn's disease: a cross-sectional study.

Authors:  M M van de Meeberg; M L Seinen; H H Fidder; M Lin; B Oldenburg; N K de Boer; G Bouma; R de Jonge; M Bulatović Ćalasan
Journal:  BMC Gastroenterol       Date:  2022-07-30       Impact factor: 2.847

8.  Impaired NFKBIE gene function decreases cellular uptake of methotrexate by down-regulating SLC19A1 expression in a human rheumatoid arthritis cell line.

Authors:  Hitoshi Imamura; Sawako Yoshina; Katsunori Ikari; Keiji Miyazawa; Shigeki Momohara; Shohei Mitani
Journal:  Mod Rheumatol       Date:  2016-01-04       Impact factor: 3.023

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.